NCTN BIQSFP ANBL1531 (NRT)
NCTN BIQSFP ANBL1531 (NRT)
基本信息
- 批准号:10892605
- 负责人:
- 金额:$ 161.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:1 year oldAccelerationAcute Myelocytic LeukemiaAdolescentBrain Stem GliomaCanadaCancer CenterCause of DeathCell TherapyChildChild SupportChildhoodChildhood LeukemiaClinicalClinical TrialsClinical Trials DesignCollectionComplicationCountryDevelopmentDiagnosisDiseaseEligibility DeterminationEnrollmentFamilyFoundationsFunctional disorderHormonalImmunotherapyInstitutionInterdisciplinary StudyLaboratoriesLate EffectsMalignant Childhood NeoplasmMalignant NeoplasmsMissionMolecularNational Cancer InstituteNational Clinical Trials NetworkNeuroblastomaOrganOutcomePediatric HospitalsPediatric Oncology GroupPharmaceutical PreparationsPopulation HeterogeneityPrognosisQuality of lifeRare DiseasesResearchResearch PersonnelScientistSecond Primary CancersSiteSurvival RateTissuesUniversitiesWorkanticancer researchcancer therapychemotherapychildhood cancer survivorclinical translationdesignexperiencehealth related quality of lifehigh riskimprovedimproved outcomeinnovationmembernovel therapeutic interventionoperationreproductivesmall moleculetranslational study
项目摘要
PROJECT SUMMARY
Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the
prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood
cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number
of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous
leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma,
still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children
greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and
tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more
than 40% of the 500,000 survivors of childhood cancer (estimated as of 2020) experiencing a significant health
related quality of life complication from childhood cancer and its treatment. Thus, despite our advances,
development of new therapeutic approaches must be a priority for childhood cancer basic, translational and
clinical researchers. The Children’s Oncology Group (COG), the world’s largest organization devoted
exclusively to childhood and adolescent cancer research, was founded 20 years ago. The COG’s
multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220
leading children’s hospitals, universities, and cancer centers. This proposal is for COG, as part of the National
Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work
that supports the mission of improving the outcome for all children with cancer. The COG will design and
conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the
molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using
innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic
approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies.
The COG research portfolio importantly also includes clinical trials focused on improving the quality of life for
children with cancer and childhood cancer survivors. As more than 90% of children diagnosed with cancer in
the US are treated at COG member institutions, COG has the ability to offer a diverse population of children
with cancer and their families the opportunity to participate in innovative research. This research effort includes
allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation
for discovery and accelerating the most promising research efforts conducted in laboratories around the world.
The proposal is for support of the COG Network Operations Center, clinician-scientists who develop and
conduct research, and for member sites to participate through enrollment of eligible subjects.
项目概要
自从 60 多年前引入化疗治疗儿童白血病以来,
儿童癌症的预后显着改善 儿童总体 5 年生存率。
在化疗之前,许多癌症都是致命的,但现在有 84% 的癌症已取得进展。
然而,儿童癌症的发病率有限,大约 50% 的儿童患有急性骨髓性癌症
白血病、50%的儿童患有高危神经母细胞瘤、90%以上的儿童患有脑干胶质瘤,
在美国,癌症仍然是儿童疾病死亡的主要原因。
此外,癌症治疗的后期影响,包括永久性器官和疾病。
组织损伤、荷尔蒙和生殖功能障碍以及第二种癌症是特别值得关注的,更多
500,000 名儿童癌症幸存者(截至 2020 年估计)中超过 40% 的健康状况不佳
因此,尽管我们取得了进步,但儿童癌症及其治疗引起的相关生活质量并发症。
开发新的治疗方法必须成为儿童癌症基础、转化和治疗的优先事项
儿童肿瘤学小组(COG)是世界上最大的致力于临床研究的组织。
COG 成立于 20 年前,专门从事儿童和青少年癌症研究。
多学科研究团队由 9,000 多名成员组成,在 220 多个国家/地区开展研究
该提案是针对 COG 的,作为国家计划的一部分。
癌症研究所 (NCI) 国家临床试验网络 (NCTN) 继续开展合作研究工作
COG 将设计和支持改善所有癌症儿童治疗结果的使命。
对患有癌症的儿童进行临床转化研究,以加深对癌症的了解
儿科恶性肿瘤的分子基础,并且具有改善结果的最大潜力。
适合罕见疾病研究的创新临床试验设计,我们将研究治疗新颖
方法包括但不限于靶向小分子药物、免疫疗法和细胞疗法。
重要的是,COG 研究组合还包括专注于改善患者生活质量的临床试验
癌症儿童和儿童癌症幸存者 90% 以上的儿童被诊断患有癌症。
美国在COG成员机构接受治疗,COG有能力为不同人群的儿童提供服务
与癌症及其家人一起参与创新研究的机会。
允许收集和注释所有癌症儿童的生物样本,提供基础
发现并加速世界各地实验室进行的最有前景的研究工作。
该提案旨在支持 COG 网络运营中心、开发和
进行研究,并让会员站点通过注册符合条件的受试者来参与。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Douglas S. Hawkins其他文献
Development of Curative Therapies for Ewing Sarcomas by Interdisciplinary Cooperative Groups in Europe
欧洲跨学科合作小组开发尤文肉瘤治疗方法
- DOI:
10.1055/s-0035-1545263 - 发表时间:
2015-05-01 - 期刊:
- 影响因子:0
- 作者:
T. Bölling;G. Braun‐Munzinger;Stefan Burdach;Gabriele Calaminus;Alan W. Craft;Olivier Delattre;M. Deley;U. Dirksen;B. Dockhorn‐Dworniczak;Jürgen Dunst;S. Engel;Andreas Faldum;Birgit Fröhlich;Helmut Gadner;U. Göbel;G. Gosheger;Jendrik Hardes;Douglas S. Hawkins;Lars Hjorth;C. Hoffmann;Heinrich Kovar;J. Kruseová;R. Ladenstein;Ivo Leuschner;I. Lewis;Odile Oberlin;M. Paulussen;Jenny Potratz;A. Ranft;C. Rossig;Christian Rübe;R. Sauer;O. Schober;Andreas Schuck;B. Timmermann;F. Tirode;H. V. D. Berg;F. Valen;Volker Vieth;N. Willich;W. Winkelmann;Jeremy Whelan;R. Womer - 通讯作者:
R. Womer
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma
横纹肌肉瘤儿童的种系基因检测和生存结果
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:13.8
- 作者:
Bailey A Martin;He Li;Michael E Scheurer;Dana L Casey;Shannon Dugan;Deborah A Marquez;D. Muzny;Richard A. Gibbs;D. Barkauskas;David Hall;Douglas R Stewart;J. Schiffman;Matthew T McEvoy;Javed Khan;D. Malkin;C. Linardic;B. Crompton;J. Shern;S. Skapek;R. Venkatramani;Douglas S. Hawkins;A. Sabo;Sharon E. Plon;Philip J. Lupo - 通讯作者:
Philip J. Lupo
Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.
用于高危神经母细胞瘤、高级别胶质瘤和难治性/复发性儿童实体瘤的 I 期拓扑替康准备方案。
- DOI:
- 发表时间:
2000 - 期刊:
- 影响因子:0
- 作者:
Julie R. Park;Julie R. Park;Julie R. Park;John T. Slattery;T. Gooley;Douglas S. Hawkins;Douglas S. Hawkins;Karen L. Lindsley;J. Villablanca;K. Matthay;Jean E. Sanders;Jean E. Sanders - 通讯作者:
Jean E. Sanders
Investigating the heterogeneity of alkylating agents’ efficacy and toxicity between sexes: A systematic review and meta‐analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)
调查烷化剂在性别之间的功效和毒性的异质性:比较环磷酰胺和异环磷酰胺的随机试验的系统回顾和荟萃分析(MAIAGE 研究)
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:3.2
- 作者:
B. Fresneau;Allan Hackshaw;Douglas S. Hawkins;M. Paulussen;James R. Anderson;I. Judson;S. Litière;U. Dirksen;Ian J. Lewis;H. M. V. D. Berg;Natalie Gaspar;H. Gelderblom;Jeremy Whelan;Alan V. Boddy;Keith Wheatley;J. Pignon;F. Vathaire;M. C. L. Deley;G. Teuff - 通讯作者:
G. Teuff
Maternal and birth characteristics and childhood rhabdomyosarcoma: a report from the Children’s Oncology Group
母亲和出生特征以及儿童横纹肌肉瘤:儿童肿瘤学组的报告
- DOI:
- 发表时间:
2014 - 期刊:
- 影响因子:2.3
- 作者:
P. Lupo;Heather E. Danysh;S. Skapek;Douglas S. Hawkins;Logan G. Spector;Renke Zhou;M. Okcu;Karin E Papworth;Erik B. Erhardt;S. Grufferman - 通讯作者:
S. Grufferman
Douglas S. Hawkins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Douglas S. Hawkins', 18)}}的其他基金
COG NCTN Network Group Operations Center - Year 10 STAR Act COG) Outcomes & Survivorship (LTE) Committee
COG NCTN 网络集团运营中心 - 第 10 年 STAR 法案 COG) 结果
- 批准号:
10918928 - 财政年份:2023
- 资助金额:
$ 161.95万 - 项目类别:
COG NCTN Network Group Operations Center - Year 10 Administrative Supplements
COG NCTN 网络集团运营中心 - 10 年级行政补充资料
- 批准号:
10888036 - 财政年份:2023
- 资助金额:
$ 161.95万 - 项目类别:
COG NCTN Network Group Operations Center - Year 9 Supplement
COG NCTN 网络集团运营中心 - 9 年级补充材料
- 批准号:
10665291 - 财政年份:2022
- 资助金额:
$ 161.95万 - 项目类别:
Multi-Year COG Supplement Long-term Follow-Up-Outcomes/Survivorship
多年 COG 补充长期随访结果/生存率
- 批准号:
10478732 - 财政年份:2014
- 资助金额:
$ 161.95万 - 项目类别:
相似国自然基金
基于增广拉格朗日函数的加速分裂算法及其应用研究
- 批准号:12371300
- 批准年份:2023
- 资助金额:43.5 万元
- 项目类别:面上项目
肠菌源性丁酸上调IL-22促进肠干细胞增殖加速放射性肠损伤修复的机制研究
- 批准号:82304065
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于肌红蛋白构象及其氧化还原体系探究tt-DDE加速生鲜牛肉肉色劣变的分子机制
- 批准号:32372384
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于联邦学习自动超参调整的数据流通赋能加速研究
- 批准号:62302265
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
M2 TAMs分泌的OGT通过促进糖酵解过程加速肝细胞癌恶性生物学行为的机制研究
- 批准号:82360529
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
COG NCTN Network Group Operations Center - Year 10 STAR Act COG) Outcomes & Survivorship (LTE) Committee
COG NCTN 网络集团运营中心 - 第 10 年 STAR 法案 COG) 结果
- 批准号:
10918928 - 财政年份:2023
- 资助金额:
$ 161.95万 - 项目类别:
Children's Oncology Group Statistics and Data Center
儿童肿瘤学组统计和数据中心
- 批准号:
10799432 - 财政年份:2023
- 资助金额:
$ 161.95万 - 项目类别:
COG NCTN Network Group Operations Center - Year 10 Administrative Supplements
COG NCTN 网络集团运营中心 - 10 年级行政补充资料
- 批准号:
10888036 - 财政年份:2023
- 资助金额:
$ 161.95万 - 项目类别: